• Phare
  • Validé par KD/KO

Anticorps Polyclonal de lapin anti-HER2/ErbB2

HER2/ErbB2 Polyclonal Antibody for WB, IP, IF, IHC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris et plus (1)

Applications

WB, IHC, IF-P, IP, ELISA

Conjugaison

Non conjugué

N° de cat : 18299-1-AP

Synonymes

CD340, ERBB2, HER 2, HER 2/neu, HER2, MLN 19, MLN19, NEU, NGL, p185, p185erbB2, Proto oncogene c ErbB 2, Proto oncogene Neu, TKR1



Applications testées

Résultats positifs en WBcellules 4T1, cellules HeLa, cellules MCF-7, cellules SGC-7901
Résultats positifs en IPcellules SGC-7901
Résultats positifs en IHCtissu de cancer du sein humain,
il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
Résultats positifs en IF-Ptissu de cancer du sein humain,

Dilution recommandée

ApplicationDilution
Western Blot (WB)WB : 1:2000-1:12000
Immunoprécipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochimie (IHC)IHC : 1:300-1:1200
Immunofluorescence (IF)-PIF-P : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

18299-1-AP cible HER2/ErbB2 dans les applications de WB, IHC, IF-P, IP, ELISA et montre une réactivité avec des échantillons Humain, souris

Réactivité Humain, souris
Réactivité citéerat, Humain, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène Peptide
Nom complet v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
Masse moléculaire calculée 138 kDa
Poids moléculaire observé 185 kDa
Numéro d’acquisition GenBankBC167147
Symbole du gène HER2/ErbB2
Identification du gène (NCBI) 2064
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
Conditions de stockageStocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand-binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas. This antibody raised against a synthesized peptide corresponding to 1237-1255aa of human HER2 recognizes the 185-kDa full-length glycosylated form and other lower molecular-mass forms of HER2, including the truncated form.

Protocole

Product Specific Protocols
WB protocol for HER2/ErbB2 antibody 18299-1-APDownload protocol
IHC protocol for HER2/ErbB2 antibody 18299-1-APDownload protocol
IF protocol for HER2/ErbB2 antibody 18299-1-APDownload protocol
IP protocol for HER2/ErbB2 antibody 18299-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Cell Metab

Targeting Erbin-mitochondria axis in platelets/megakaryocytes promotes B cell-mediated antitumor immunity

Authors - Zilong Zhang
humanIHC

Cell Res

Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers.

Authors - Daisong Wang
mouseWB

Small

Efficient Delivery of GSDMD-N mRNA by Engineered Extracellular Vesicles Induces Pyroptosis for Enhanced Immunotherapy

Authors - Yuqi Xing
humanIHC

Nat Commun

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Authors - Yunhua Liu
humanWB

J Immunother Cancer

Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells.

Authors - Shasha Zhao
humanWB

Cancer Res

Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer.

Authors - Jiao Wang

Avis

The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.


FH

Vanina (Verified Customer) (07-28-2021)

MDA-MB-453 cell line was transfected with different concentrations of HER2/Erbb2 siRNA for 48h. Western blot using HER2/Erbb2 rabbit Proteintech antibody (18299-1-AP) at 1:2,000 dillution confirms the HER2/Erbb2 knockdown.

  • Applications: Western Blot
  • Primary Antibody Dilution: 1:2,000
  • Cell Tissue Type: MDA-MB-453 breast cancer cell line
HER2/ErbB2 Antibody Western Blot validation (1:2,000 dilution) in MDA-MB-453 breast cancer cell line (Cat no:18299-1-AP)